A Study of Peginterferon Alfa-2a (40KD) (PEGASYS®) in Participants With Hepatitis B Envelope Antigen (HBeAg) - Positive Chronic Hepatitis B

Baltic Post-marketing Program of PEGASYS (Peg Interferon Alpha-2a 40KD) in Patients With HBeAg-positive and HBeAg-negative Chronic Hepatitis B

This single-arm study will evaluate the efficacy and safety of peginterferon alfa-2a in treatment-naive Baltic participants with Hepatitis B envelope antigen (HBeAg)-positive chronic Hepatitis B virus (HBV). All participants will receive peginterferon alfa-2a 180 micrograms (mcg) subcutaneously once weekly. Following 48 weeks of treatment, there will be a 24 week period of treatment-free follow-up. The anticipated time on study treatment is 3-12 months, and the target sample size is less than 100 participants.

Inclusion Criteria:

• Adult participants, 18-70 years of age;
• HBeAg positive, Hepatitis B surface antigen (HBsAg) positive for greater than or equal to 6 months;
• anti-HBs negative;
• Hepatitis B virus deoxyribonucleic acid (HBV DNA) greater than 5,00,000 copies/milliliters.

Exclusion Criteria:

• Previous antiviral or interferon-based therapy for chronic hepatitis B;
• Evidence of decompensated liver disease;
• Chronic liver disease other than viral hepatitis;
• Co-infection with active hepatitis A, C or D virus;
• Co-infection with human immunodeficiency virus.